Last reviewed · How we verify
Prednisone acetate 1%
Prednisone acetate is a corticosteroid that suppresses inflammatory and immune responses in the eye by inhibiting phospholipase A2 and reducing production of inflammatory mediators.
Prednisone acetate is a corticosteroid that suppresses inflammatory and immune responses in the eye by inhibiting phospholipase A2 and reducing production of inflammatory mediators. Used for Inflammation and pain following ocular surgery, Steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye.
At a glance
| Generic name | Prednisone acetate 1% |
|---|---|
| Sponsor | Kovach Eye Institute |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
As a topical ophthalmic corticosteroid, prednisone acetate penetrates ocular tissues and binds to glucocorticoid receptors, suppressing the migration of polymorphonuclear leukocytes and fibroblasts, stabilizing lysosomal membranes, and reducing capillary permeability. This results in decreased inflammation, edema, and immune-mediated responses in anterior segment eye disease.
Approved indications
- Inflammation and pain following ocular surgery
- Steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye
Common side effects
- Elevated intraocular pressure
- Posterior subcapsular cataract formation
- Secondary ocular infection
- Ocular irritation or discomfort
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss (PHASE2)
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (PHASE2)
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
- Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma (PHASE1)
- A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (PHASE2)
- A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prednisone acetate 1% CI brief — competitive landscape report
- Prednisone acetate 1% updates RSS · CI watch RSS
- Kovach Eye Institute portfolio CI